Global Chronic Cough Market Outlook 2024, Forecast To 2033
8 Mar, 2024
The chronic cough market has experienced significant growth, escalating from $7.5 billion in 2023 to $8.16 billion in 2024, with a CAGR of 8.8%, attributed to the prevalence of underlying respiratory conditions and environmental factors. Projected growth indicates a market size of $11.48 billion by 2028, with a CAGR of 8.9%, driven by emerging therapies, increasing understanding of reflux-related cough, and global smoking cessation efforts, alongside trends such as advancements in diagnostic technologies and patient-centric approaches.
Global Chronic Cough Market Key Driver
The surge in cough prevalence is anticipated to propel growth in the chronic cough market. Chronic cough cases are on the rise, leading to increased demand for effective treatments. For example, pertussis cases recorded a 41% increase in Denmark from November 2022 to April 2023, indicating the need for advanced chronic cough treatments.
Get A Free Sample Of The Global Chronic Cough Market ReportGlobal Chronic Cough Market Segments
The chronic cough market covered in this report is segmented –
1) Drug Class:Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Other Drug Classes
2) Route Of Administration:Oral, Inhalational, Injectable, Other Route of Administrations
3) End-Users:Hospitals, Homecare, Specialty Centers, Other End Users
4) Distribution Channel:Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
By Geography: The countries covered in the chronic cough market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the chronic cough market in 2023. The regions covered in the chronic cough market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Chronic Cough Industry Players
Tris Pharma Inc.; Pfizer Inc.; Johnson & Johnson Co; Bayer AG; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca plc; Glaxo SmithKline Plc; Merck KGaA; Reckitt Benckiser Group plc; Glenmark Pharmaceuticals Ltd; Teva Pharmaceutical Industries Ltd.; Mylan NV; Aurobindo Pharma Ltd.; Cipla Limited; Apotex Inc.; Hikma Pharmaceuticals Plc; Amneal Pharmaceuticals LLC; Mount Sinai Health System; Biocon Ltd.; BELLUS Health Inc.; Trevi Therapeutics Inc.; Sun Pharmaceutical Industries Ltd.; NeRRe Therapeutics Ltd.
Get The Full Global Chronic Cough Market Report
Chronic Cough Market Overview
Chronic cough refers to a cough that is persistent and lasts for a long time, usually eight weeks or more. It frequently manifests as signs of an underlying illness, such as asthma, allergies, or respiratory infections.